Diabetes therapy : research, treatment and education of diabetes and related disordersAug 29, 2026

How SGLT2 Inhibitors May Help Prevent Type 2 Diabetes: A Review of Current Evidence

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Aug 30, 2026

Abstract

Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be effective in delaying the progression of prediabetes to type 2 diabetes mellitus (T2DM).

Prediabetes is linked to a heightened risk of both microvascular and macrovascular complications.
Lifestyle changes are essential for managing prediabetes.
Several medications, including metformin and GLP-1 receptor agonists, have shown potential in preventing the onset of T2DM.
Current evidence on the use of SGLT2 inhibitors for adults with prediabetes is being reviewed.
Arguments exist both for and against the routine clinical use of SGLT2 inhibitors in this population.

Simplified

Prediabetes is a metabolic state that frequently precedes overt type 2 diabetes mellitus (T2DM) and is associated with an increased risk of micro- and macrovascular complications. Lifestyle modification remains the cornerstone of management, and several pharmacological agents, including metformin, pioglitazone, acarbose and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), have demonstrated efficacy in delaying progression to T2DM. Sodium-glucose cotransporter 2 (SGLT2) inhibitors (often referred to as gliflozins) are increasingly being investigated in this context. The aim of this review is to summarise current evidence regarding the use of SGLT2 inhibitors in adults with prediabetes and to discuss the arguments for and against their routine clinical use.

Full Text

Full text is available at the source.

View Full Text ↗

How SGLT2 Inhibitors May Help Prevent Type 2 Diabetes: A Review of Current Evidence

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief